Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VTVT
VTVT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VTVT News
Wall Street Analysts Adjust NIO Ratings
Mar 13 2026
Benzinga
Wall Street Analysts Adjust Ratings
Mar 13 2026
Benzinga
Wall Street Analysts Adjust Ratings
Mar 12 2026
Benzinga
vTv Therapeutics Reports 2025 Financials and Pipeline Progress
Mar 11 2026
NASDAQ.COM
vTv Therapeutics Q4 Earnings Exceed Expectations
Mar 10 2026
seekingalpha
Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target
Jan 23 2026
Benzinga
vTv Therapeutics Initiated with Buy Rating and $67 Price Target
Jan 05 2026
Benzinga
vTv Therapeutics Upgraded to Zacks Rank #2 (Buy) Reflecting Positive Earnings Outlook
Dec 24 2025
NASDAQ.COM
vTv Therapeutics Submits Phase 2 Study Protocol for Cadisegliatin in Type 2 Diabetes
Dec 18 2025
Globenewswire
vTv Therapeutics Submits Phase 2 Trial Protocol for Cadisegliatin in Type 2 Diabetes
Dec 18 2025
Newsfilter
Everything You Should Know About vTv Therapeutics (VTVT) Upgrade to Buy Rating
Nov 11 2025
NASDAQ.COM
vTv Therapeutics Files for Resale of 15.9 Million Class A Shares
Oct 03 2025
SeekingAlpha
vTv Therapeutics to Take Part in INNODIA Symposium During EASD 61st Annual Meeting
Sep 15 2025
Newsfilter
VTv Therapeutics Obtains $80 Million Through PIPE Financing
Sep 02 2025
NASDAQ.COM
HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $36 Price Target
Aug 13 2025
Benzinga
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 12 2025
Yahoo Finance
Show More News
